IFG
AVXL icon

Investors Financial Group’s Anavex Life Sciences AVXL Stock Holding History

Investors Financial Group’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-36,650
Closed -$636K – 17
2021
Q4 		$636K Buy
36,650
+12,650
+53% +$240K 0.3% 89
2021
Q3 		$431K Buy
+24,000
New +$478K 0.23% 118

Other funds holding AVXL

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Investors Financial Group's AVXL Position: Q1 2022 in Review

Investors Financial Group sold out of Anavex Life Sciences (AVXL) in Q1 2022, closing a stake of 36,650 shares — an estimated $636K sold.

Investors Financial Group first reported a position in AVXL in Q3 2021 and held it in 2 quarters. The position peaked at $636K in Q4 2021. 139 funds tracked by Wall St. Rank hold AVXL as of Q1 2022.

  • Investors Financial Group reported no remaining Anavex Life Sciences position as of Q1 2022 after selling out during the quarter.
  • Investors Financial Group sold 36,650 Anavex Life Sciences shares in Q1 2022, an estimated $636K.
  • Investors Financial Group first reported a position in Anavex Life Sciences in Q3 2021 and held it in 2 quarters.
  • Investors Financial Group's Anavex Life Sciences position peaked at $636K in Q4 2021.
  • 139 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2022.

Based on Investors Financial Group's 13F filing for Q1 2022.